Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-04-23
2011-11-22
Chandra, Gyan (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
08063013
ABSTRACT:
The present invention provides methods and kits for diagnosing and treating glaucoma.
REFERENCES:
patent: 5145871 (1992-09-01), Cavazza
patent: 5364884 (1994-11-01), Varma et al.
patent: 6207450 (2001-03-01), Sheffield et al.
patent: 6248571 (2001-06-01), Schmidt et al.
patent: 6248867 (2001-06-01), Nguyen et al.
patent: 6613563 (2003-09-01), Sosnowski et al.
patent: 2008/0194515 (2008-08-01), Kimko et al.
patent: 9820889 (1998-05-01), None
patent: 0061774 (2000-10-01), None
patent: 0068247 (2000-11-01), None
patent: 0077021 (2000-12-01), None
patent: 02077006 (2002-10-01), None
patent: 02085909 (2002-10-01), None
Fuchshofer et al., Invest Ophthalmol. Vis Sci. 48: 715-726, 2007.
Fuchshofer et al., Exp. Eye Res. 88: 1020-1032, 2009.
Miyazono, “Positive and negative regulation of TGF-b signaling”, J. Cell Science, 113:1101-1109 (2000).
Mohan, et al., “Bone morphogenic proteins 2 and 4 and their receptors in the adults human cornea,” Invest. Ophthalmol. & Vis. Sci. 39(13):2626-2636 (1998).
Morrison JC, et al., “Optic nerve head extracellular matrix in primary optic atrophy and experimental glaucoma,” Arch. Ophthalmol. 108:1020-1024 (1990).
Murphy, M., et al., “Suppression Subtractive Hybridization Identified High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells”, J. Biol. Chem. 274(9):5830-5834 (1999).
Nickel et al., “The Crystal Structure of the BMP-2:BMPR-IA Complex and the Generation of BMP-2 Antagonists”, J Bone & Joint Surgery 83-A(suppl 1):S1-7—S1-14 (2001).
Nohno, T., et al., “Identification of a Human Type II Receptor for Bone Morphogenetic Protein-4 That Forms Differential Heteromeric Complexes with Bone Morphogenetic Protein Type I Receptors”, J. Biol. Chem. 270(38):22522-22526 (1995).
Nonner et al., “Bone morphogenic proteins (BMP6 and BMP7) enhance the protective effect of neurotrophins on cultured septal cholinergic neurons during hypoglycemia,” Journal of Neurochemistry 77:691-699 (2001).
Oakley et al., “The Human Glucocorticoid Receptor β Isoform”, J. Biol. Chem. 271(16):9550-9559 (1996).
Oakley et al., “Expression and Subcellular Distribution of the β-lsoform of the Human Glucocorticoid Receptor”, Endocrinology 138(11):5028-5038 (1997).
Obata et al., “Expression of transforming growth factor-beta superfamily receptors in rat eyes,” Acta. Ophthalmol. Scand. 77:151-156 (1999).
Pang I-H, et al., “Human ocular perfusion organ culture: a versatile ex vivo model for glaucoma research,” J. Glaucoma 9:468-479 (2000).
Pena et al, “Transforming growth factor beta isoforms in human optic nerve heads,” Br. J. Ophthalmol. 83:209-218 (1999).
Picht et al, “Transforming growth factor β2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development,” Graefes Arch. Clin. Exp. Ophthalmol. 239:199-207 (2001).
Quigley HA, et al., “Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis,” Invest. Ophthalmol. Vis. Sci. 36(5):774-786 (1995).
Quigley HA, “Neuronal death in glaucoma,” Prog. Retin. Eye Res. 18:39-57 (1999).
Quigley HA, et al., “Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats,” Invest. Ophthalmol. Vis. Sci. 41(11):3460-3466 (2000).
Reddi, “Bone morphonegetic proteins: an unconventional approach to isolation of first mammalian morphogens,” Cytokine & Growth Factor Rev. 8(1):11-20 (1997).
Reddi, “Bone morphogenic proteins and skeletal development: the kidney-bone connection,” Pediatr Nephrol. 14:598-601 (2000).
Rohen JW, “Why is Intraocular Pressure Elevated in Chronic Simple Glaucoma? Anatomical considerations.” Ophthalmology 90:758-765 (1983).
Steely HT, et al., “The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells,” Invest. Ophthalmol. Vis. Sci. 33(7): 2242-2250 (1992).
Steely HT, et al., “The Similarity of protein expression in trabecular meshwork and Iamina cribrosa: implications for glaucoma,” Exp. Eye Res. 70:17-30 (2000).
Stone EM, et al., “Identification of a gene that causes primary open angle glaucoma,” Science 275:668-670 (1997).
Strong, N. P., “How optometrists screen for glaucoma: A survey”, Ophthal. Physiol. Opt., 12:3-7 (1992).
Ten Dijke, PP, et al., “Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity”, Oncogene 8(10):2879-2887 (1993).
Tripathi RC, et al., “Analysis of Human Aqueous Humor for Epidermal Growth Factor,” Exp. Eye Res. 53:407-409 (1991).
Tripathi RC, et al., “Detection, quantification, and significance of basic fibroblast growth factor in the aqueous humor of man, cat, dog and pig,” Exp. Eye Res. 54:447-454 (1992).
Tripathi RC, et al., “Trabecular cells of the eye express messenger RNA for transforming growth factor-beta 1 and secrete this cytokine,” Invest. Ophthalmol. Vis. Sci. 34(8):2562-2569 (1993).
Tripathi RC, et al., “Aqueous Humor in Glaucomatous Eyes Contains an Increased Level of TFG-β2,” Exp. Eye Res. 59:723-727 (1994).
Tripathi RC, et al., “Immunolocalization of bFGF in the Trabecular Meshwork and Detection of its mRNA in Trabecular Cells,” Exp. Eye Res. 58:503-507 (1994).
Tripathi RC, et al., “Trabecular Cells Express the TFG-β2 Gene and Secrete the Cytokine,” Exp. Eye Res. 58:523-528 (1994).
Tripathi RC, et al., “Clinical implications of aqueous humor growth factors in glaucoma,” in Ritch R., Shields, M.B., Krupin, T. (eds). The Glaucomas, 2nd ed. St Louis: Mosby-Year; pp. 71-87 (1996).
Trousse F et al., “BMP4 mediates apoptotic cell death in the developing chick eye,” J. Neurosci. 21(4):1292-1301 (2001).
Tuck MW, et al., “Relative effectiveness of different modes of glaucoma screening in optometric practice”, Ophthal. Physiol. Opt., 13:227-232 (1993).
Varma R and Minckler D, “Anatomy and pathophysiology of the retina and optic nerve.” in Ritch R., Shields, M.B., Krupin, T. (eds). The Glaucomas, 2nd ed. St Louis: Mosby-Year; pp. 139-175 (1996).
Vaughan, D. et al., In: General Ophthalmology, Appleton & Lange, Norwalk, Conn., pp. 213-230 (1992).
Vernon, SA, “Intra-Eye Pressure Range and Pulse Profiles in Normals With the Pulsair Non-Contact Tonometer”, Eye 7:134-137 (1993).
von Bubnoff A and Cho KW, “Intracellular BMP signaling regulation in vertebrates: pathway or network?” Dev. Biol. 239:1-14 (2001).
Wang W-H, et al., “Optimal procedure for extracting RNA from human ocular tissues and expression profiling of the congenital glaucoma gene FOXC1 using quantitative RT-PCR,” Molecular Vision 7:89-94 (2001).
Wilson K, et al., “Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells,” Current Eye Research 12(9):783-793 (1993).
Wordinger RJ, et al., “Cultured human trabecular meshwork cells express functional growth factor receptors,” Invest. Ophthalmol. & Vis. Sci. 39(9): 1575-1589 (1998).
Dermer, G; “Another anniversary for the war on cancer” ; Bio/Technology; 12:320 (1994).
Liu Y, et al.; The effect of bone morphogenic protein-7 (BMP-7) on functional recovery, local cerebral glucose utilization and blood flow after transient focal cerebral ischemia in rats; Brain Res.; 905:81-90 (2001).
Nishimura, et al.; The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25; Nature Gen.; 19:140-147; (1998).
Strachan, et al.; Molecular pathology; Human Molecular Genetics; Chapter 15; pp. 401-426; (1996).
Taniguchi, et al.; Clinical phenotype of a J
Clark Abbot F.
Wordinger Robert J.
Chandra Gyan
Derry Jason J.
Novartis AG
University of North Texas Health Science Center
LandOfFree
Method of treating glaucoma comprising administering a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating glaucoma comprising administering a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating glaucoma comprising administering a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275429